# Test Review Results

## Verdict: FAIL

Coverage artifact: `specs/328-bounded-review-convergence/test-coverage.json`

## Blocking Findings

### 1. Missing stale target tree execution guard coverage
**Target:** specs/328-bounded-review-convergence/tests/review-execution-regression.test.js
**Issue:** R2 and R9 require tree change revalidation and rejection before a new provider execution or state mutation. The tests validate stale tree handling only through ReviewEvidenceInput.validateTarget for independent evidence, but there is no provider-execution fixture that changes or mismatches the current target tree SHA and proves the provider boundary is not started and flow state/evidence bytes remain unchanged.
**Required change:** Add one spec-local executable provider review test that supplies a stale tree SHA or mutates the target tree before review execution, asserts provider startup is not called, and asserts canonical evidence files and flow state are unchanged.
**Why blocking:** This is an explicit acceptance requirement with no corresponding spec-local test coverage for the provider execution path.

### 2. Missing completed-review idempotence coverage
**Target:** specs/328-bounded-review-convergence/tests/review-execution-regression.test.js
**Issue:** R3 requires a valid PASS or ADVISORY result to complete the current review step exactly once without another review invocation. Existing tests assert normalized PASS/ADVISORY results have rerunAllowed false, but they do not execute the review pipeline twice or prove a second unchanged review invocation is rejected before provider startup and without state mutation.
**Required change:** Add a spec-local executable test that records a PASS or ADVISORY review completion, invokes the same phase/task/tree review again, and asserts executionStarted is false or equivalent, provider startup is not called, and flow state is unchanged.
**Why blocking:** The exactly-once/no-second-invocation acceptance behavior is not covered by an executable test against the production execution path.


## Advisory Findings

No advisory findings.